Dermatologists generally know that the sensitivity of many pathogens to the antibiotics used to treat them is decreasing, experts say. But many dermatologists may not appreciate their specialty’s role in potentially fueling the problem.
Popular media coverage of purported links between isotretinoin and inflammatory bowel disease (IBD) are largely overblown, as are patients’ concerns regarding the risks of oral contraceptive pills (OCPs) for acne, according to an expert.
Even though bacteria such as Propionibacterium acnes share the same genus and species, says an expert, recent research suggests that different P. acnes strains may behave differently, which could have profound implications for acne treatment.
With isotretinoin disappearing from continuous medical education (CME), says an expert, dermatologists must take the initiative in promoting best practices for this indispensable acne drug.
Even though patients may present with clinically similar acne, says an expert, their expectations and preferences for particular treatments may differ vastly.
With acne presenting in increasingly younger patients, new guidelines developed by the American Acne and Rosacea Society (AARS) promote more consistent care for pediatric patients, according to an expert.
Recent developments regarding acne and rosacea in skin of color include studies showing that combination topical products for acne appear safe in this population, and the fact that rosacea is perhaps more prevalent than many might expect.
Misconceptions, lack of data leave derms coming up short on contraceptive prescriptions for acne treatment
Dermatologists’ prescribing of oral contraceptive pills (OCPs) and antibiotics for acne leaves room for improvement, according to an expert.
Once-daily application of Sansrosa (brimonidine tartrate/BT gel, Galderma) 0.5 percent has proven safe and effective for treating the persistent facial erythema of rosacea, according to the results of a phase 2 trial.
When it comes to newer healthcare delivery models, experts say accountable care organizations (ACOs) may impact dermatology only in highly competitive markets. Still, dermatologists worry that ACOs could set primary care physicians (PCPs) and specialists at odds, and that specialists' roles in shared-savings programs remain highly uncertain in today's healthcare arena.